StreetInsider.com News Articles

Form 4 Pharvaris N.V. For: Jul 13 Filed by: Modig Berndt

Wed, 15 Jul 2026 13:08:00 -0400

si-local-file:///var/storage/secattach/20260715/26773342.html

Form 4 Pharvaris N.V. For: Jul 13 Filed by: Modig Berndt

Wed, 15 Jul 2026 13:08:00 -0400

si-local-file:///var/storage/secattach/20260715/26773342.html

Wells Fargo Starts Pharvaris B.V. (PHVS) at Overweight

Wed, 15 Jul 2026 05:11:37 -0400

Wells Fargo analyst Yanan Zhu initiates coverage on Pharvaris B.V. (NASDAQ: PHVS) with a Overweight rating and a price target of $55.00.

The analyst comments: “We highlight key differentiations of deucrictibant, an oral HAE therapy w/ injectable drug-like efficacy, representing a compelling new option both as an on-demand therapy and in the prophylaxis setting. In addition, the bradykinin B2 receptor-targeted MOA acts at the key signaling bottleneck and may confer broadest coverage of bradykinin mediated angioedemas. We see $1.8B peak sales potential across deucrictibant indications.

PHVS's deucrictibant demonstrated strong efficacy as on-demand therapy (ODT) in phase 3, with faster timeto-onset of symptom

Wells Fargo Starts Pharvaris B.V. (PHVS) at Overweight

Wed, 15 Jul 2026 05:11:37 -0400

Wells Fargo analyst Yanan Zhu initiates coverage on Pharvaris B.V. (NASDAQ: PHVS) with a Overweight rating and a price target of $55.00.

PHVS's deucrictibant demonstrated strong efficacy as on-demand therapy (ODT) in phase 3, with faster timeto-onset of symptom

Form 4 Pharvaris N.V. For: Jul 11 Filed by: Lu Peng

Tue, 14 Jul 2026 15:46:00 -0400

si-local-file:///var/storage/secattach/20260714/26768032.html

Form 4 Pharvaris N.V. For: Jul 11 Filed by: Lu Peng

Tue, 14 Jul 2026 15:46:00 -0400

si-local-file:///var/storage/secattach/20260714/26768032.html

Form 144 Pharvaris N.V. Filed by: Modig Berndt

Mon, 13 Jul 2026 16:39:00 -0400

si-local-file:///var/storage/secattach/20260713/26762945.html

Form 144 Pharvaris N.V. Filed by: Modig Berndt

Mon, 13 Jul 2026 16:39:00 -0400

si-local-file:///var/storage/secattach/20260713/26762945.html

FDA accepts Pharvaris NDA for oral HAE attack treatment deucrictibant

Mon, 06 Jul 2026 06:50:14 -0400

Pharvaris (Nasdaq: PHVS) announced that the U.S. Food and Drug Administration has accepted its New Drug Application for deucrictibant immediate-release capsule (20 mg) for the on-demand treatment of hereditary angioedema attacks, according to a company statement.

The FDA has set a PDUFA target action date of April 23, 2027.

Deucrictibant is an oral bradykinin B2 receptor antagonist. The company claims it would be the first oral therapy of its type approved to treat HAE attacks, if the NDA is approved.

The NDA draws on clinical data covering treatment of more than 1,300 HAE attacks. The pivotal Phase 3 study, RAPIDe-3, enrolled participants aged

Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks

Mon, 06 Jul 2026 06:50:00 -0400

If approved, deucrictibant will be the first oral bradykinin B2 receptor antagonist to treat HAE attacks
NDA includes positive data from successful clinical program demonstrating rapid relief and sustained response to resolution of HAE attack symptoms and a well-tolerated safety profile
PDUFA action date set for April 23, 2027

ZUG, Switzerland, July 06, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1

Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks

Mon, 06 Jul 2026 06:50:00 -0400

If approved, deucrictibant will be the first oral bradykinin B2 receptor antagonist to treat HAE attacks
NDA includes positive data from successful clinical program demonstrating rapid relief and sustained response to resolution of HAE attack symptoms and a well-tolerated safety profile
PDUFA action date set for April 23, 2027

Form 4 Pharvaris N.V. For: Jun 29 Filed by: Schikan Johannes Gerardus Christiaan Petrus

Wed, 01 Jul 2026 19:06:00 -0400

si-local-file:///var/storage/secattach/20260701/26722521.html

Form 4 Pharvaris N.V. For: Jun 29 Filed by: Schikan Johannes Gerardus Christiaan Petrus

Wed, 01 Jul 2026 19:06:00 -0400

si-local-file:///var/storage/secattach/20260701/26722521.html

Form 4 Pharvaris N.V. For: Jun 29 Filed by: Lesage Anne

Wed, 01 Jul 2026 19:03:00 -0400

si-local-file:///var/storage/secattach/20260701/26722510.html

Form 4 Pharvaris N.V. For: Jun 29 Filed by: Lesage Anne

Wed, 01 Jul 2026 19:03:00 -0400

si-local-file:///var/storage/secattach/20260701/26722510.html

Form 144 Pharvaris N.V. Filed by: Lesage Anne

Tue, 30 Jun 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260630/26714229.html

Form 144 Pharvaris N.V. Filed by: Lesage Anne

Tue, 30 Jun 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260630/26714229.html

Form 144 Pharvaris N.V. Filed by: Lesage Anne

Tue, 30 Jun 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260630/26714234.html

Form 144 Pharvaris N.V. Filed by: Lesage Anne

Tue, 30 Jun 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260630/26714234.html

Form 144 Pharvaris N.V. Filed by: Schikan Johannes Gerardus Christiaan Petrus

Tue, 30 Jun 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260630/26714226.html

Form 144 Pharvaris N.V. Filed by: Schikan Johannes Gerardus Christiaan Petrus

Tue, 30 Jun 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260630/26714226.html

Form 4 Pharvaris N.V. For: Jun 25 Filed by: Lesage Anne

Mon, 29 Jun 2026 18:41:00 -0400

si-local-file:///var/storage/secattach/20260629/26707957.html

Form 4 Pharvaris N.V. For: Jun 25 Filed by: Lesage Anne

Mon, 29 Jun 2026 18:41:00 -0400

si-local-file:///var/storage/secattach/20260629/26707957.html

Form 4 Pharvaris N.V. For: Jun 25 Filed by: Lu Peng

Mon, 29 Jun 2026 18:18:00 -0400

si-local-file:///var/storage/secattach/20260629/26707916.html

Form 4 Pharvaris N.V. For: Jun 25 Filed by: Lu Peng

Mon, 29 Jun 2026 18:18:00 -0400

si-local-file:///var/storage/secattach/20260629/26707916.html